Stocks To Watch: CarTrade Tech, Fertiliser Shares, Vedanta, Sun Pharma, Cipla and more

Stocks To Watch: CarTrade Tech, Fertiliser Shares, Vedanta, Sun Pharma, Cipla and more

SUMMARY

From Vedanta to Cipla and CarTrade Tech, these are the stocks to watch out for ahead of Monday’s trading session.

Profile imageBy CNBCTV18.com June 23, 2024, 9:13:21 PM IST (Published)

CarTrade Tech Block Deal

Image count1 / 8

CarTrade Tech | Highdell Investment and Macritichie Investments likely to sell 7% and 3.4% stake respectively on Monday via block deals. The floor price of ₹820 per share is a 4.3% discount to Friday’s closing price. Deal size of the block is said to be ₹400 crore with an upsize option of another ₹100 crore. There will be a 75-day lock-in period for the sellers. At the end of the March quarter, Highdell Investments held a 17.36% stake, while Macritchie Investments held a 16.3% stake.

Vedanta share price target

Image count2 / 8

Vedanta | Parent company Vedanta Resources ‘strongly denies’ any news report of promoters planning a stake sale in Vedanta Ltd.

Cipla Share Price, Cipla Stock, Cipla shares

Image count3 / 8

Cipla | USFDA issues form 483 with six observations for its Goa facility. The plant was inspected between June 10 to June 21, 2024. The Goa plant has been under a warning letter since February 2020. The company’s Indore plant has been under a warning letter since November 2023.

Fertiliser Stocks

Image count4 / 8

Fertiliser Stocks | GST Council sends request to reduce GST on fertilisers to Group of Ministers GoM on rate rationalisation.

Sun Pharma Share Price, Sun Pharma Share, Sun Pharma GERD drug, Sun Pharma stock, Sun Pharma shares, Sun Pharma Takeda Pharma, Sun Pharma drug for gastrointestinal issues,

Image count5 / 8

Sun Pharma | Announces outcome of Phase-1 obesity trial of GL0034 (Utreglutide) which is a GLP-1 inhibitor drug. It belongs to the same class as Ozempic, Wegovy from Novo Nordisk and Mounjaro from Eli Lilly. The drug is still in the very early stages of development and adds to prospects of the company’s specialty business. GLP-1 drugs hit nearly $50 billion in sales in 2023 and likely to grow to $100 billion by 2029.

Lupin

Image count6 / 8

Lupin | Gets Establishment Inspection Report (EIR) from the USFDA for its Somerset manufacturing facility with a Voluntary Action Indicated (VAI) status. The facility was inspected between May 7 to May 17, 2024.

mcx share price

Image count7 / 8

MCX | Board shortlists names of candidates for the post of its next MD & CEO. The company will initiate seeking regulatory approvals for the appointment.

Prestige Estates QIP

Image count8 / 8

Prestige Estates | Board approves raising up to ₹5,000 crore via QIP and other methods.

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *